All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
DUBLIN – Medigene AG is getting a slice of the action from sales of Amgen Inc.’s pioneering oncolytic virus therapy Imlygic (talimogene laherparepvec), in an intellectual property licensing deal involving its spin-off company Catherex Inc., which Amgen is acquiring for $10.5 million up front plus regulatory and sales-based milestones, as well as single-digit royalty payments on Imlygic sales.